Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with donafenib and sindilimab after curative resection for MVI-positive hepatocellular carcinoma
ChiCTR2200059858Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib and sintilimab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: 2-year recurrence-free survival rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200059858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059858.